Shanghai SILE

Shanghai SILE Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics, particularly targeting deubiquitinating enzymes (DUBs). The company leverages its proprietary platform to develop high-potency and high-selectivity inhibitors for targets such as USP1 and USP7, which play critical roles in DNA damage repair and immune evasion in cancer. Their lead program, SILE-101, is a USP1 inhibitor designed to treat homologous recombination deficiency (HRD) positive tumors, potentially as a monotherapy or in combination with PARP inhibitors. Founded by industry veterans with experience at global pharmaceutical firms, the company aims to address unmet medical needs in oncology and immunology through precision medicine. Shanghai SILE has secured significant venture capital funding to advance its pipeline from discovery into clinical development.